Biogen's Growth Portfolio Overtakes Legacy MS as Apellis Integration and Imminent Readouts Reshape the Story

High-dose SPINRAZA, LEQEMBI IQLIK, and the SYFOVRE/Empaveli acquisition drive a confident inflection.

BIIB · Earnings Call · 2026-07-29

The Growth Portfolio Inflection

Biogen's second-quarter 2026 earnings call delivered the message investors have awaited for years: the growth portfolio has officially overtaken the legacy MS business. CEO Christopher Viehbacher opened with a clear declaration: “our growth portfolio now is greater than our legacy MS portfolio” — Christopher A. Viehbacher, President and Chief Executive Officer · 2026-07-29. The quarter's revenue performance underscored this shift, with core pharmaceutical revenue up 4% year-over-year and the growth portfolio generating over $1 billion, up 24% year-over-year. The engine is the recently closed Apellis acquisition, adding SYFOVRE and Empaveli, which contributed $128 million in the half-quarter post-close. CFO Robin Kramer noted: “We are pleased to be increasing our total revenue guidance from a mid-single-digit percentage decrease to a mid-single-digit percentage increase.” — Robin C. Kramer, Chief Financial Officer · 2026-07-29 The guidance hike reflects both the strength of the base business and the anticipated contribution from the acquired portfolio. The High dose SPINRAZA launch has exceeded internal expectations, with President North America Alisha Alaimo reporting: “SPINRAZA high-dose is exceeding the original launch of SPINRAZA in both start forms and GRADs in the first 13 weeks of launch.” — Alisha A. Alaimo, President, North America (or President, Biogen US) · 2026-07-29 This is critical in a competitive SMA market, where the franchise's durability is now reinforced by a pipeline asset, salinursen, which recently received breakthrough therapy designation.

Pipeline Catalysts

The second half of the call pivoted to the late-stage pipeline, which management framed as imminent. Priya Singhal, Head of Development, highlighted that the company is entering a multiyear registrational cycle:

We are now entering a multiyear registrational cycle beginning with SLE data by the end of this year and followed by multiple catalysts extending through the remainder of the decade.
Priya Singhal, Head of Development (or EVP, Head of Development) · 2026-07-29

Five Phase 3 readouts are expected within the next four quarters, spanning lupus (SLE and CLE), antibody-mediated rejection (AMR), and Dravet syndrome. The AMR opportunity alone is estimated at over $2 billion, and the company is investing aggressively in prelaunch activities. Meanwhile, the BTK inhibitor BIIB091 achieved proof-of-concept in relapsing-remitting MS, but management is deliberately pausing further investment given the crowded competitive landscape—a testament to disciplined capital allocation.

Financial Implications

The Apellis acquisition is a double-edged sword financially. Management expects it to dilute non-GAAP EPS by roughly $0.85 in 2026, but to be accretive in 2027, with at least $250 million in run-rate synergies by end of 2027. The company ended the quarter with $1.3 billion cash and $6.8 billion net debt, and it continues to generate strong free cash flow. The latest quarterly filing (Q1 2026) shows revenue of $2.5B, but the Q2 call reports $2.7B total revenue, reflecting the Apellis consolidation. This inversion—a rising growth portfolio against a declining legacy base—is exactly the story management has been crafting since the Apellis deal was announced. Prior quarters set the stage: in Q4 2025, CEO Viehbacher already noted that growth products were outpacing MS declines (“So far, the growth products in the last two years certainly last year, did outstrip the decline of EMS” — Christopher Viehbacher, Chief Executive Officer · 2026-02-06). The Q2 2026 call confirms that trend has now crossed a critical threshold. With the pipeline readouts looming and a refreshed commercial organization, Biogen is positioning itself as a growth story again, not just a defensive hold. The market has responded with a 25% rally over the past 90 days, though the stock remains far from its 2015 peak—suggesting there is still room for the narrative to build.